Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × balixafortide × Breast × Clear all

Phase

Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Cyclophosphamide 152 Docetaxel 147 Paclitaxel 142 Trastuzumab 134 Capecitabine 118 Tamoxifen 107 Letrozole 92 Epirubicin 79 Doxorubicin 75 exemestane 66 Anastrozole 66 Fulvestrant 62 Fluorouracil 55 Radiotherapy 53 Carboplatin 53 pertuzumab 49 Gemcitabine 45 Vinorelbine 39 Goserelin 36 eribulin 32 130-nm albumin-bound paclitaxel 32 Lapatinib 28 Zoledronic Acid 26 Methotrexate 26 Chemotherapy, Adjuvant 26 Bevacizumab 26 ribociclib 24 palbociclib 24 pegfilgrastim 21 Drug Therapy 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03786094 2023-11-01

FORTRESS

Spexis AG

Phase 3 Terminated

432 enrolled 13 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡